Daniel P Barboriak
ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel P Barboriak as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06319027 · Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE TrialECOG-ACRIN Cancer Research Group · recruiting · Glioblastoma, IDH-Wildtype · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT06319027
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:19 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 100 citationsRCR 4.0
- 73 citationsRCR 1.7
- 66 citationsRCR 2.3
- 51 citationsRCR 2.0
- Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Neuro Oncol · 201341 citationsRCR 1.4
- An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab.Magn Reson Med · 201033 citationsRCR 1.1
- Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.Neuro Oncol · 201830 citationsRCR 1.3
- 20 citationsRCR 1.0